A Closer Look at BBO-11818, One of the RAS Initiative’s Newest Drugs
Preclinical results for an anticancer drug developed under the auspices of the NCI RAS Initiative were recently reported in Cancer Discovery. The drug, BBO-11818, hindered tumor growth or shrank tumors in laboratory and mouse models of non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer.
09.16.2026
